InspireMDSTU:II2 -2.42%41 Receivables Turnover is 1.50 as of Mar. 2026. GuruFocus rates STU:II2 with a GF Score™ of 41/100 and a GF Value™ of €1.54 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 811 Medical Devices & Instruments companies, InspireMD ranks better than 50.68% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. InspireMD's Revenue for the
three
months ended in Mar. 2026 was €2.94 Mil. InspireMD's average Accounts Receivable for the
three
months ended in Mar. 2026 was €1.96 Mil.
Hence, InspireMD's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.50.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
InspireMD Receivables Turnover Related Terms
InspireMD Receivables Turnover Historical Data
* Premium members only.
The historical data trend for InspireMD's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:II2 vs TELA, BDMD, PAVM: Receivables Turnover Comparison
For the Medical Devices subindustry, InspireMD's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InspireMD Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, InspireMD's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where InspireMD's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InspireMD (STU:II2) has a Receivables Turnover of 1.50 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on InspireMD and its competitors. According to the industry distribution chart, InspireMD ranks #400 out of 811 companies in the Medical Devices & Instruments industry, placing it in the top 49.3%.
Is InspireMD's Receivables Turnover too high?
InspireMD's current Receivables Turnover is 1.50. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. InspireMD's value of 1.50 is 72.8% below this industry median. Based on the distribution chart, InspireMD ranks #400 out of 811 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, InspireMD has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InspireMD's Receivables Turnover compare to TELA and BDMD?
According to the Medical Devices & Instruments industry distribution chart, InspireMD ranks #400 out of 811 companies for Receivables Turnover. This puts InspireMD in the upper half of its industry. The industry median Receivables Turnover is 5.51. InspireMD's value of 1.50 is 72.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InspireMD's current Receivables Turnover of 1.50 is 72.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on InspireMD and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InspireMD's current Receivables Turnover is 1.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InspireMD stock overvalued right now?
Based on GuruFocus' analysis, InspireMD (STU:II2) is currently considered Possible Value Trap. The stock's GF Value™ is €1.54, compared to a current price of €0.61 — trading 60.7% below its estimated fair value. The current Receivables Turnover is 1.50 and 72.8% below the Medical Devices & Instruments industry median of 5.51. InspireMD's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For InspireMD (STU:II2), the current Receivables Turnover is 1.50 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InspireMD (STU:II2) Overvalued in 2026?
Based on GuruFocus' analysis, InspireMD stock appears to be undervalued.
The current stock price of €0.61 is trading 60.7% below its estimated GF Value™ of €1.54.
GuruFocus considers InspireMD to be Possible Value Trap.
Key valuation signals for STU:II2:
Receivables Turnover: 1.50
GF Value™: €1.54 vs. price of €0.61 (60.7% below fair value)
Industry Position: 72.8% below the Medical Devices & Instruments median (#400 of 811)
No single metric tells the full story. See the STU:II2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
41GF Score
Get the complete analysis for STU:II2
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:II2 has been successfully added to your 
